Molence· @MolenceBio · X·· 17 天前AI 评分57
AI 导读
Molence Bio 公布其计算设计的 VHH 以 VHH-Fc 融合形式结合 CXCR6 表达细胞,EC50 为 39 nM。在 cAMP 实验中,30 nM CXCL16 使响应降至仅含 forskolin 对照的 70.6%,加入 167 nM 该 VHH 后恢复至 92.6%,作者据此认为该结合体对 CXCL16 诱导的 CXCR6 信号具有拮抗作用。该条是 15 条系列帖的第 7 条,前一条报告了靶向 4-1BB 的激动型设计。
正文 · 原文
7/15 🧬 A designed VHH can antagonize a GPCR.
The CXCR6 design bound receptor-expressing cells with an EC50 of 39 nM, tested as a VHH-Fc fusion.
In the cAMP assay, 30 nM CXCL16 reduced the response to 70.6% of the forskolin-only control. Adding 167 nM VHH restored it to 92.6%.
This experiment supports antagonism of CXCL16-induced CXCR6 signaling by a computationally designed binder.
#DrugDiscovery
6/15 ⚡ Designed VHHs can activate 4-1BB. In a six-hour reporter assay, two Mol-1-workflow designs tested as VHH-Fc fusions achieved activation EC50 values of 0.05 and 0.22 nM, compared with 0.43 nM for Utomilumab. VHH 01 also showed an SPR KD of 3.5 nM. Both designs had favorable biophysical profiles, including high monomeric purity, thermal stability and low self-interaction. The design objective here was receptor agonism. #DrugDiscovery在 X 查看被引用的帖子
来源:Molence · x.com